Lantern Pharma Launches AI Module to Enhance Cancer Combination Therapies Development

Lantern Pharma (NASDAQ: LTRN), a leader in AI-driven oncology drug development, has unveiled a new AI-powered module within its RADR(R) platform designed to predict the efficacy of combination therapies involving DNA-damaging agents and DNA damage response inhibitors. This innovation, supported by a peer-reviewed analysis of 221 clinical trials, promises to streamline the design of cancer treatment regimens, potentially cutting development time and costs by up to one-third. The technology has already played a pivotal role in designing Lantern’s FDA-cleared Phase 1B/2 trial for triple-negative breast cancer, combining LP-184 and olaparib. Lantern Pharma is now exploring opportunities to license and commercialize this system across various oncology indications, marking a significant step forward in personalized cancer treatment strategies.